An international team of researchers led by the University Hospital and University of Bonn, as well as the universities of ...
Opus Genetics (IRD) receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in ...
Opus Genetics announced positive 3- and 6-month results from the low-dose cohort 1 of BIRD-1, the ongoing phase 1/2 ...
Stocktwits on MSN
IRD stock hits over 5-year highs – Opus Genetics experimental therapy shows early promise in retinal diseases trial
Opus Genetics’ OPGx-BEST1 is being developed for inherited retinal diseases caused by mutations in the BEST1 gene. ・Three of five patients showed meaningful improvement in vision, while three patients ...
A joint team effort led by Dr. Haruhisa Inoue (Professor, Department of Cell Growth and Differentiation, CiRA) has established iPS cells from two patients with EYS-associated retinal dystrophies ...
MeiraGTx Holdings plc announced promising results from a first-in-human study published in The Lancet, involving a gene therapy treatment for children with AIPL1-associated retinal dystrophy, ...
Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Bart Leroy, MD, PhD, speaks ...
Opus Genetics, Inc. IRD stock is surging on Wednesday after the company reported positive three- and six-month results from ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results